NASDAQ:BIVV - Bioverativ Stock Price, Price Target & More

$104.98 0.00 (0.00 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$104.98
Today's RangeN/A
52-Week Range$48.14 - $105.01
VolumeN/A
Average Volume3.03 million shs
Market Capitalization$11.36 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Bioverativ (NASDAQ:BIVV)

Bioverativ logoBioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive BIVV News and Ratings via Email

Sign-up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:BIVV
CUSIPN/A
Phone+1-781-6634400

Debt

Debt-to-Equity RatioN/A
Current Ratio2.00%
Quick Ratio1.89%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio27.48
P/E Growth1.96

Sales & Book Value

Annual Sales$1.17 billion
Price / Sales9.72
Cash Flow$2.8754 per share
Price / Cash36.51
Book Value$8.29 per share
Price / Book12.66

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$355.60 million
Net Margins30.43%
Return on Equity40.99%
Return on Assets22.79%

Miscellaneous

Employees460
Outstanding Shares108,220,000

How to Become a New Pot Stock Millionaire

Bioverativ (NASDAQ:BIVV) Frequently Asked Questions

What is Bioverativ's stock symbol?

Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."

How were Bioverativ's earnings last quarter?

Bioverativ Inc (NASDAQ:BIVV) posted its earnings results on Tuesday, February, 13th. The biotechnology company reported $0.76 earnings per share for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. The biotechnology company had revenue of $328.70 million for the quarter, compared to analyst estimates of $325.89 million. Bioverativ had a return on equity of 40.99% and a net margin of 30.43%. View Bioverativ's Earnings History.

When is Bioverativ's next earnings date?

Bioverativ is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Bioverativ.

What price target have analysts set for BIVV?

13 equities research analysts have issued twelve-month price targets for Bioverativ's shares. Their predictions range from $47.00 to $80.00. On average, they anticipate Bioverativ's share price to reach $65.00 in the next twelve months. View Analyst Ratings for Bioverativ.

What are Wall Street analysts saying about Bioverativ stock?

Here are some recent quotes from research analysts about Bioverativ stock:
  • 1. William Blair analysts commented, "We are dropping coverage of Bioverativ , Inc. following the completion of its acquisition by Sanofi (SNY $39.90). Our final rating on Bioverativ was Market Perform." (3/8/2018)
  • 2. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (1/8/2018)
  • 3. Cowen Inc analysts commented, "Bioverativ reported Q2 revenue of $289MM (+38% Y/Y) versus consensus of." (8/4/2017)

Who are some of Bioverativ's key competitors?

Who are Bioverativ's key executives?

Bioverativ's management team includes the folowing people:
  • Brian S. Posner, Independent Chairman of the Board (Age 55)
  • John G. Cox, Chief Executive Officer, Director (Age 54)
  • John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
  • Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
  • Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
  • Richard Brudnick, Executive Vice President - Business Development (Age 60)
  • Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
  • Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
  • Alexander J. Denner Ph.D., Independent Director (Age 47)
  • Louis J. Paglia, Independent Director (Age 59)

Has Bioverativ been receiving favorable news coverage?

News articles about BIVV stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bioverativ earned a media sentiment score of 0.05 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Bioverativ?

Shares of BIVV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioverativ's stock price today?

One share of BIVV stock can currently be purchased for approximately $104.98.

How big of a company is Bioverativ?

Bioverativ has a market capitalization of $11.36 billion and generates $1.17 billion in revenue each year. Bioverativ employs 460 workers across the globe.

How can I contact Bioverativ?

Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected]


MarketBeat Community Rating for Bioverativ (BIVV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe BIVV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIVV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bioverativ (NASDAQ:BIVV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Bioverativ in the last 12 months. Their average twelve-month price target is $65.00, suggesting that the stock has a possible downside of 38.08%. The high price target for BIVV is $80.00 and the low price target for BIVV is $47.00. There are currently 12 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.082.202.442.44
Ratings Breakdown: 0 Sell Rating(s)
12 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $65.00$64.00$62.5714$60.7857
Price Target Upside: 38.08% downside39.04% downside0.40% upside5.90% upside

Bioverativ (NASDAQ:BIVV) Consensus Price Target History

Price Target History for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ:BIVV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2018William BlairReiterated RatingHoldLowView Rating Details
1/24/2018ArgusReiterated RatingBuy -> HoldLowView Rating Details
1/24/2018Credit Suisse GroupReiterated RatingNeutral -> NeutralLowView Rating Details
1/23/2018Raymond JamesDowngradeStrong-Buy -> HoldLowView Rating Details
1/23/2018Morgan StanleyUpgradeUnderweight -> Equal WeightLowView Rating Details
1/22/2018Jefferies GroupDowngradeBuy -> HoldLowView Rating Details
1/22/2018Piper JaffrayDowngradeOverweight -> NeutralLowView Rating Details
1/18/2018Royal Bank of CanadaBoost Price TargetMarket Perform$68.00LowView Rating Details
11/20/2017Deutsche BankSet Price TargetHold$53.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$58.00HighView Rating Details
8/4/2017CowenReiterated RatingBuy$80.00HighView Rating Details
6/28/2017WedbushReiterated RatingMarket PerformLowView Rating Details
4/24/2017GabelliDowngradeBuy -> HoldLowView Rating Details
3/28/2017Leerink SwannSet Price TargetBuy$62.00LowView Rating Details
3/27/2017Stifel NicolausBoost Price TargetBuy -> Buy$54.00 -> $57.00LowView Rating Details
3/13/2017Goldman SachsDowngradeBuy -> Neutral$55.00MediumView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Bioverativ (NASDAQ:BIVV) Earnings History and Estimates Chart

Earnings by Quarter for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ:BIVV) Earnings Estimates

Current Year EPS Consensus Estimate: $3.82 EPS
Next Year EPS Consensus Estimate: $4.18 EPS

Bioverativ (NASDAQ BIVV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018        
2/13/2018Q4 2017$0.75$0.76$325.89 million$328.70 millionViewN/AView Earnings Details
10/26/2017Q3 2017$0.55$0.80$285.45 million$291.60 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.71$0.88$269.00 million$289.10 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.62$0.65$250.03 million$259.10 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Bioverativ (NASDAQ:BIVV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Bioverativ (NASDAQ BIVV) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 97.18%
Insider Trading History for Bioverativ (NASDAQ:BIVV)
Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ BIVV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2017Brian S PosnerDirectorBuy1,000$59.19$59,190.006,693View SEC Filing  
8/7/2017Louis J PagliaDirectorBuy2,000$59.70$119,400.005,056View SEC Filing  
6/28/2017Diantha DuvallInsiderSell818$60.47$49,464.462,128View SEC Filing  
5/30/2017Alexander J DennerDirectorBuy90,000$55.93$5,033,700.005,001View SEC Filing  
5/26/2017Louis J PagliaDirectorBuy2,000$57.76$115,520.003,056View SEC Filing  
5/24/2017Brian S PosnerDirectorBuy2,000$53.86$107,720.004,993View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bioverativ (NASDAQ BIVV) News Headlines

Source:
DateHeadline
Bioverativ (BIVV) Raised to "Outperform" at CowenBioverativ (BIVV) Raised to "Outperform" at Cowen
www.americanbankingnews.com - April 19 at 7:29 PM
Bioverativ Highlights the Impact of Humanitarian Aid in HemophiliaBioverativ Highlights the Impact of Humanitarian Aid in Hemophilia
www.businesswire.com - April 17 at 9:22 AM
Bioverativs (BIVV) Buy Rating Reaffirmed at Jefferies GroupBioverativ's (BIVV) Buy Rating Reaffirmed at Jefferies Group
www.americanbankingnews.com - April 11 at 6:44 PM
Bioverativ Inc (BIVV) Receives Consensus Recommendation of "Hold" from AnalystsBioverativ Inc (BIVV) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 8:16 AM
Bioverativ (BIVV) Price Target Increased to $79.00 by Analysts at Jefferies GroupBioverativ (BIVV) Price Target Increased to $79.00 by Analysts at Jefferies Group
www.americanbankingnews.com - March 27 at 12:34 PM
Bioverativ (BIVV) Lifted to Equal Weight at Morgan StanleyBioverativ (BIVV) Lifted to Equal Weight at Morgan Stanley
www.americanbankingnews.com - March 26 at 7:40 PM
Bioverativ (BIVV) Downgraded to Hold at Raymond James FinancialBioverativ (BIVV) Downgraded to Hold at Raymond James Financial
www.americanbankingnews.com - March 26 at 7:09 PM
Cascadian Therapeutics (CASC) versus Bioverativ (BIVV) Financial AnalysisCascadian Therapeutics (CASC) versus Bioverativ (BIVV) Financial Analysis
www.americanbankingnews.com - March 25 at 8:56 AM
Sucampo Pharmaceuticals (SCMP) versus Bioverativ (BIVV) Head-To-Head ComparisonSucampo Pharmaceuticals (SCMP) versus Bioverativ (BIVV) Head-To-Head Comparison
www.americanbankingnews.com - March 22 at 3:24 PM
Stellar Gene Therapy And Gene Editing Innovators - A Specialty ReportStellar Gene Therapy And Gene Editing Innovators - A Specialty Report
seekingalpha.com - March 13 at 9:13 AM
Bioverativ (BIVV) Earns "Hold" Rating from William BlairBioverativ (BIVV) Earns "Hold" Rating from William Blair
www.americanbankingnews.com - March 8 at 2:07 PM
Bioverativ Inc. (BIVV) Begins Dosing in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease - StreetInsider.comBioverativ Inc. (BIVV) Begins Dosing in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease - StreetInsider.com
www.streetinsider.com - March 8 at 9:15 AM
Sanofi (SNY) Completes Acquisition of Bioverativ (BIVV) - StreetInsider.comSanofi (SNY) Completes Acquisition of Bioverativ (BIVV) - StreetInsider.com
www.streetinsider.com - March 8 at 9:15 AM
Wired News – Bioverativ Doses First Patient in Phase-3 Study of BIVV009 for Treatment of Cold Agglutinin DiseaseWired News – Bioverativ Doses First Patient in Phase-3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
finance.yahoo.com - March 8 at 9:15 AM
Bioverativ Inc (BIVV) Receives Consensus Rating of "Hold" from AnalystsBioverativ Inc (BIVV) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 7 at 11:45 AM
Bioverativ Inc. (BIVV) Begins Dosing in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin DiseaseBioverativ Inc. (BIVV) Begins Dosing in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
www.streetinsider.com - March 7 at 9:10 AM
Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin DiseaseBioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
finance.yahoo.com - March 6 at 8:56 AM
$333.33 Million in Sales Expected for Bioverativ Inc (BIVV) This Quarter$333.33 Million in Sales Expected for Bioverativ Inc (BIVV) This Quarter
www.americanbankingnews.com - March 6 at 1:58 AM
Woodford Investment Management Ltd Decreases Stake in Bioverativ Inc (BIVV)Woodford Investment Management Ltd Decreases Stake in Bioverativ Inc (BIVV)
www.americanbankingnews.com - March 5 at 2:25 PM
WINTON GROUP Ltd Has $7.35 Million Position in Bioverativ Inc (BIVV)WINTON GROUP Ltd Has $7.35 Million Position in Bioverativ Inc (BIVV)
www.americanbankingnews.com - March 4 at 2:29 PM
Bioverativ Inc (BIVV) Shares Sold by Credit Agricole S ABioverativ Inc (BIVV) Shares Sold by Credit Agricole S A
www.americanbankingnews.com - March 4 at 5:38 AM
Bioverativ Inc (BIVV) Shares Bought by Bank of New York Mellon CorpBioverativ Inc (BIVV) Shares Bought by Bank of New York Mellon Corp
www.americanbankingnews.com - March 4 at 4:45 AM
Bioverativ Inc (BIVV) Holdings Decreased by State of Tennessee Treasury DepartmentBioverativ Inc (BIVV) Holdings Decreased by State of Tennessee Treasury Department
www.americanbankingnews.com - March 3 at 10:12 AM
Bioverativ Inc (BIVV) Shares Sold by Eaton Vance ManagementBioverativ Inc (BIVV) Shares Sold by Eaton Vance Management
www.americanbankingnews.com - March 2 at 12:05 PM
What Does A Double-Bottom Base Look Like? This Top Biotech Stock Formed A Great OneWhat Does A Double-Bottom Base Look Like? This Top Biotech Stock Formed A Great One
finance.yahoo.com - March 2 at 8:58 AM
Bioverativ Inc (BIVV) Shares Bought by Jackson Square Partners LLCBioverativ Inc (BIVV) Shares Bought by Jackson Square Partners LLC
www.americanbankingnews.com - February 28 at 3:55 PM
Bioverativ Inc (BIVV) Shares Sold by Liberty Mutual Group Asset Management Inc.Bioverativ Inc (BIVV) Shares Sold by Liberty Mutual Group Asset Management Inc.
www.americanbankingnews.com - February 28 at 12:56 PM
Clovis Oncology (CLVS) Soars: Stock Adds 6.6% in SessionClovis Oncology (CLVS) Soars: Stock Adds 6.6% in Session
www.zacks.com - February 28 at 8:58 AM
Bioverativ Inc (BIVV) Holdings Trimmed by Rhumbline AdvisersBioverativ Inc (BIVV) Holdings Trimmed by Rhumbline Advisers
www.americanbankingnews.com - February 28 at 7:52 AM
BlackRock Inc. Raises Stake in Bioverativ Inc (BIVV)BlackRock Inc. Raises Stake in Bioverativ Inc (BIVV)
www.americanbankingnews.com - February 28 at 5:05 AM
Bioverativ Inc (BIVV) Position Raised by Arizona State Retirement SystemBioverativ Inc (BIVV) Position Raised by Arizona State Retirement System
www.americanbankingnews.com - February 28 at 4:28 AM
Heres Why You Must Add Hologic (HOLX) to Your Portfolio NowHere's Why You Must Add Hologic (HOLX) to Your Portfolio Now
finance.yahoo.com - February 27 at 5:22 PM
Bioverativ Inc (BIVV) Holdings Increased by California Public Employees Retirement SystemBioverativ Inc (BIVV) Holdings Increased by California Public Employees Retirement System
www.americanbankingnews.com - February 27 at 5:20 AM
Bioverativ Inc (BIVV) Holdings Boosted by Spark Investment Management LLCBioverativ Inc (BIVV) Holdings Boosted by Spark Investment Management LLC
www.americanbankingnews.com - February 25 at 2:30 PM
OppenheimerFunds Inc. Has $77.33 Million Stake in Bioverativ Inc (BIVV)OppenheimerFunds Inc. Has $77.33 Million Stake in Bioverativ Inc (BIVV)
www.americanbankingnews.com - February 25 at 1:20 PM
American International Group Inc. Has $12.08 Million Holdings in Bioverativ Inc (BIVV)American International Group Inc. Has $12.08 Million Holdings in Bioverativ Inc (BIVV)
www.americanbankingnews.com - February 25 at 4:04 AM
The Manufacturers Life Insurance Company  Reduces Stake in Bioverativ Inc (BIVV)The Manufacturers Life Insurance Company Reduces Stake in Bioverativ Inc (BIVV)
www.americanbankingnews.com - February 24 at 5:54 AM
Teacher Retirement System of Texas Sells 76,980 Shares of Bioverativ Inc (BIVV)Teacher Retirement System of Texas Sells 76,980 Shares of Bioverativ Inc (BIVV)
www.americanbankingnews.com - February 24 at 5:14 AM
Heres Why You Must Add Haemonetics (HAE) to Your PortfolioHere's Why You Must Add Haemonetics (HAE) to Your Portfolio
finance.yahoo.com - February 23 at 5:17 PM
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in SessionSangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in Session
www.zacks.com - February 23 at 9:00 AM
 Analysts Expect Bioverativ Inc (BIVV) Will Post Quarterly Sales of $333.33 Million Analysts Expect Bioverativ Inc (BIVV) Will Post Quarterly Sales of $333.33 Million
www.americanbankingnews.com - February 18 at 5:46 AM
Bioverativ Inc (BIVV) Files 10-K for the Fiscal Year Ended on December 31, 2017Bioverativ Inc (BIVV) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 15 at 8:27 AM
Abiomeds Extended FDA Nod for Impella Boosts Women HealthAbiomed's Extended FDA Nod for Impella Boosts Women Health
finance.yahoo.com - February 14 at 5:03 PM
Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia AHaemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A
finance.yahoo.com - February 14 at 9:26 AM
Bioverativ Reports Fourth Quarter and Full Year 2017 PerformanceBioverativ Reports Fourth Quarter and Full Year 2017 Performance
finance.yahoo.com - February 14 at 9:26 AM
Bioverativ (BIVV) Releases Quarterly  Earnings Results, Beats Expectations By $0.73 EPSBioverativ (BIVV) Releases Quarterly Earnings Results, Beats Expectations By $0.73 EPS
www.americanbankingnews.com - February 13 at 7:08 PM
[$$] 3 Biotechs That Could Benefit From an M&A Frenzy[$$] 3 Biotechs That Could Benefit From an M&A Frenzy
finance.yahoo.com - February 13 at 4:10 PM
Bioverativ Inc (BIVV) Receives Average Rating of "Hold" from BrokeragesBioverativ Inc (BIVV) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 9:44 AM
Bioverativ Inc (BIVV) Sees Significant Drop in Short InterestBioverativ Inc (BIVV) Sees Significant Drop in Short Interest
www.americanbankingnews.com - February 10 at 2:02 AM
ACT NOW: Monteverde & Associates PC Announces an Investigation of Bioverativ Inc. - BIVVACT NOW: Monteverde & Associates PC Announces an Investigation of Bioverativ Inc. - BIVV
finance.yahoo.com - February 8 at 4:08 PM

SEC Filings

Bioverativ (NASDAQ:BIVV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bioverativ (NASDAQ:BIVV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bioverativ (NASDAQ BIVV) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.